Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · IEX Real-Time Price · USD
2.170
-0.150 (-6.47%)
At close: Apr 18, 2024, 4:00 PM
2.100
-0.070 (-3.23%)
After-hours: Apr 18, 2024, 7:58 PM EDT
Company Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders.
Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Adial Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jul 30, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Cary John Claiborne MBA |
Contact Details
Address: 1180 Seminole Trail, Suite 495 Charlottesville, Virginia 22901 United States | |
| Phone | 434-422-9800 |
| Website | adialpharma.com |
Stock Details
| Ticker Symbol | ADIL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001513525 |
| CUSIP Number | 00688A106 |
| ISIN Number | US00688A2050 |
| Employer ID | 80-0667150 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Cary John Claiborne MBA | Chief Executive Officer, President and Director |
| Dr. Bankole A. Johnson DSc, FRCPsych, M.D., M.Phil, Ph.D. | Founder and Chief Medical Officer |
| Joseph A. M. Truluck M.B.A., MBA | Chief Financial Officer, Treasurer and Secretary |
| Tony Goodman | Chief Operating Officer and Director |
| John R. Martin J.D. | Chief Legal Officer |
| Catherine Fratila | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | 424B5 | Filing |
| Apr 18, 2024 | 8-K | Current Report |
| Apr 16, 2024 | 8-K | Current Report |
| Apr 12, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 1, 2024 | 10-K | Annual Report |
| Mar 14, 2024 | D | Notice of Exempt Offering of Securities |
| Mar 6, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 25, 2024 | 424B5 | Filing |
| Jan 24, 2024 | EFFECT | Notice of Effectiveness |